Skip to main content
. 2023 Dec 11;14:1325462. doi: 10.3389/fimmu.2023.1325462

Table 1.

Patient characteristics.

Characteristic No. of patients %
[Median age (range), years 70 (27–89)]
Sex 
 Male
 Female
 
123
48
 
71.9
28.1
Cancer type 
 Head and neck cancer
 Urothelial cancer
 Renal cell cancer
 Gastric cancer
 Esophageal cancer
 Malignant pleural mesothelioma
 MSI-high solid tumors a
 
50
42
37
20
10
6
6
 
29.2
24.6
21.6
11.7
5.8
3.5
3.5
Histological subtype 
 Squamous cell carcinoma
 Urothelial carcinoma
 Clear cell carcinoma
 Adenocarcinoma
 Epithelioid mesothelioma
 Sarcomatoid mesothelioma
 Adenoid cystic carcinoma
 Neuroendocrine carcinoma
 Salivary duct carcinoma
 Not otherwise specified
 
54
42
37
26
3
3
1
1
1
3
 
31.6
24.6
21.6
15.2
1.8
1.8
0.6
0.6
0.6
1.8
ECOG performance status 
 0
 1
 2
 3
 4
 
46
100
17
7
1
 
26.9
58.5
9.9
4.1
0.6
Number of prior systemic therapies 
 0
 1
 ≥2
 
2
112
57
 
1.2
65.5
33.3
ICI regimen 
 Nivolumab
 Pembrolizumab
 
121
50
 
70.8
29.2

MSI, microsatellite instability; ICI, immune checkpoint inhibitor.

a

MSI-high solid tumors included colorectal cancer (n = 4), cancer of unknown primary (n = 1), and bile duct cancer (n = 1).